Dr Sanborn on Early Efficacy and Security Knowledge With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC
“[There was also] a phase 1 dose escalation and expansion study of single-agent sigvotatug vedotin, SGNB6A-001 [NCT04389632]. In that study,…
Dr Sanborn on Early Efficacy and Security Knowledge With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC Read More